Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus standard of care for previously untreated advanced non-clear cell renal cell carcinoma
NL-OMON55837Phase 2Active, not recruiting
- Sponsor
- Goethe University Frankfurt
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab and sunitinib in non-clear cell renal cell carcinoma (nccRCC) (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Overall survival rate at 12 months. Started Apr 2021; status: active, not recruiting.
02
Drugs
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NL-OMON55837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55837.